THERAPEUTIC TRIALS OF RADIOGALLIUM (Ga 72)
- 1 December 1952
- journal article
- research article
- Published by American Medical Association (AMA) in A.M.A. Archives of Internal Medicine
- Vol. 90 (6) , 785-789
- https://doi.org/10.1001/archinte.1952.00240120060006
Abstract
RESULTS of studies of the distribution of gallium and its excretion pattern and toxicity in experimental animals have been reported by Dudley and associates1and by King and others.2Clinical trials in the radioactive use of the isotope Ga72as a possible diagnostic agent for the early localization of malignancies involving bone have been reported by Mulry and Dudley3and by King and associates.2cBrucer and associates4have reported upon the results of a therapeutic trial of Ga72. Radiogallium,31GA72, is produced by neutron bombardment of natural gallium (Ga39, Ga71) with thermal neutrons, resulting in a mixture of radioactive gallium (Ga70and Ga72). Ga70has a half life of 20 minutes and plays no important biological role. Ga72has a half life of 14.3 hours and is a beta and gamma emitter. The mean effective beta energy equals 0.45 mev, while the gamma emission is 1.59 times as energetic asThis publication has 0 references indexed in Scilit: